In the context of an introduction to your coverage, how do you evaluate names in the medtech space? Mr. Zimmerman: The lens we look through is consistency of execution, whether internal expectations ...

We had the chance to interview you a couple years ago, and when we spoke in October 2023, your company was mainly focused on advancing the drug-eluting version of its CanGaroo bioenvelope. What is the ...

In the context of an introduction to your coverage, could you define the life sciences space, and discuss how it differs from the biotech or medtech space? Ms. Utterback: The life science companies ...

It’s been a few years since we featured the company. So could you give us a brief history and some milestones for Aclarion? Mr. Ness: Certainly. We successfully completed an IPO in April of 2022. And ...

Tell us briefly about Picard Medical and the history of SynCardia Total Artificial Heart. Mr. Schnegelsberg: Let me start with SynCardia and then go to Picard. SynCardia is a company with a long ...

For readers who may just be hearing about HeartBeam, explain to us what clinical problem you are trying to solve and why hasn’t that been able to be solved with existing cardiac monitoring tools? Mr.

Complete Access to New Interviews, the Archive, and all Special Reports.